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resources were derived from public sources. One and two-way sensitivity analy-
ses were performed for key input variables. Budget impact analysis extrapolates 
results of the (CM), using prevalence data, to a health plan with 1 million covered 
lives. An alternate time-dependent model addresses the impact associated with 
the sequencing of diagnostic tests. Results: The CM model predicts a base-case 
savings of $280 per patient for the diagnostic pathway that includes the novel IBS 
diagnostic blood panel. Sensitivity analyses predict a range of cost savings of $120 
- $439. Budget impact analysis predicts a base case savings of $1,080,232 to the 
plan or $0.09 on a per member per month basis for the diagnostic pathway with 
the novel IBS diagnostic blood panel. The time dependent model indicates that 
the potential cost savings associated with the novel IBS blood test are attenuated 
over time. ConClusions: Current literature suggests that extensive diagnostic 
testing to diagnose IBS is not necessary. This economic evaluation indicates that 
the inclusion of a novel IBS diagnostic blood panel in the diagnostic process has 
the potential for significant cost savings due to the avoidance of unnecessary 
testing.
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objeCtives: Irritable bowel syndrome presents a significant burden to patients 
and to the healthcare system in Mexico. An IBS diagnosis is based on Rome crite-
ria; however, laboratory tests and diagnostic procedures are required to exclude 
organic conditions such as inflammatory bowel disease (IBD). A new IBS diagnostic 
blood panel has been developed which tests for the presence of two biomarkers 
associated with IBS-D. This analysis assesses the cost impact to the Mexican private 
practice. Methods: Budget impact analysis (BIA) was based on a cost-minimization 
(CM) decision model developed to compare the costs associated with two possible 
diagnostic pathways: (1) diagnostic pathway with a new IBS diagnostic blood panel 
and (2) exclusionary diagnostic pathway (i.e. standard of care) and applied to the 
Mexican population. Model structure was based on current literature and guidance 
from IBS expert clinicians. Direct medical expenses for laboratory tests, diagnos-
tic procedures and visit costs were included in Mexican pesos and weighted by 
utilization rates provided by practicing gastroenterologists in private practice in 
Mexico. The indirect cost estimate was based on the literature and only included 
absenteeism, adjusted for per capita income. The base case assumes that 75% of 
patients who receive a positive test result will proceed to IBS-D treatment. For the 
BIA, it is assumed that 30% of IBS-D patients will seek care, and clinicians use the 
test for 50% of patients presenting with IBS-D symptoms. Results: The CM model 
predicts per patient savings with the IBS diagnostic panel of Mex$1,688 (Mex$35,019 
vs. Mex$36,707). Cost neutrality occurs if 44% of the “positive test” patients receive 
IBS-D treatment. The BIA predicts a net savings to the Mexican healthcare system 
of Mex$794,158,235. ConClusions: Inclusion of a novel IBS diagnostic blood panel 
in the diagnostic process has the potential for significant cost savings due to the 
avoidance of downstream testing.
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objeCtives: DuoResp® Spiromax® (budesonide + formoterol fumarate dihydrate) 
is a fixed-dose combination (FDC) of inhaled corticosteroid (ICS) + long-acting beta 
agonist (LABA) in a novel dry powder inhaler (DPI). A five year economic model was 
developed from a healthcare payer perspective to assess the impact of potentially 
improved inhalation technique on unscheduled healthcare events and costs, when 
switching adult patients with persistent asthma and chronic obstructive pulmonary 
disease (COPD) from market-leading DPIs in Spain – Symbicort® Turbuhaler® and 
Seretide® Accuhaler® – to DuoResp® Spiromax®. Methods: The eligible patient 
population was estimated from current confirmed Spanish asthma and COPD diag-
nosis rates, with the proportion receiving FDCs based on market research data. 
Costs of unscheduled healthcare events were taken from publicly available Spanish 
sources. The frequency of poor inhalation technique with the market-leading DPIs, 
and the associated increased risk of unscheduled healthcare events, were taken 
from a large (n= 1,664) cross-sectional Italian study. The hypothetical reduction in 
poor inhalation technique with DuoResp® Spiromax® was an assumption based 
on the novel attributes of the Spiromax® inhaler. Results: The model estimated 
that 266,657 adult patients used Symbicort® Turbuhaler® and 296,905 Seretide® 
Accuhaler® – and were therefore eligible to receive DuoResp® Spiromax® – annu-
ally, with 115,996 (43.5%) and 102,432 (34.5%) exhibiting poor inhalation technique, 
respectively. The total cost of unscheduled healthcare events associated with poor 
inhalation technique was estimated to be € 11.54 million annually. Assuming a hypo-
thetical uptake of DuoResp® Spiromax® increasing from 6% in year 1 to 18% in year 
4 and 5, an estimated 51,633 unscheduled healthcare events were avoided due to 
the predicted improvement in inhalation technique with DuoResp® Spiromax® 
compared with other DPIs, resulting in cost savings totalling € 4.79 million over five 
years. ConClusions: Introducing DuoResp® Spiromax® may reduce the occur-
rence of unscheduled healthcare events compared with market-leading DPIs, poten-
tially resulting in cost savings.
treatment. ConClusions: Inclusion of a novel IBS diagnostic blood panel in the 
diagnostic pathway has the potential for significant cost savings due to the avoid-
ance of unnecessary testing.
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objeCtives: UK guidelines for the diagnosis of IBS in patients who meet diagnos-
tic criteria include FBC, ESR, C - reactive protein and testing for coeliac disease to 
exclude other diseases. Despite these recommendations, referral for procedures 
such as flexible sigmoidoscopy, colonoscopy and ultrasound scanning continue 
and in the majority of this patient group, are considered to be unnecessary, sub-
sequently placing an increased cost burden to National Health Services (NHS). A 
novel IBS diagnostic blood panel has been developed which tests for the presence 
of two biomarkers associated with IBS-D. This analysis estimates the potential 
cost impact to the NHS by introducing this test into the diagnostic pathway of 
IBS. Methods: Budget impact was based on a cost-minimization model to com-
pare the costs associated with two possible diagnostic pathways: (1) with a novel 
IBS diagnostic blood panel and (2) exclusionary pathway and applied to the UK 
population 18-65yrs old. Model structure was based on current literature/ guidance 
from IBS expert. Direct medical expenses include, labs, diagnostic procedures, 
visits in £ and weighted by utilization provided by a practicing gastroenterologist 
in the UK. Results: Gastroscopy, flexible sigmoidoscopy, and colonoscopy were 
the most common diagnostic (instrumental) procedures reported with estimated 
utilization rates of 55%, 55% and 35%, respectively. Corresponding charges were 
£200, £400 and £400, respectively. Net savings in the base case of £57 favored 
the IBS diagnostic blood panel pathway (assumes 75% of test positive patients 
receive IBS-D treatment) vs the exclusionary pathway. If clinicians use the test 
50% of the time for the 30% of the estimated 446,382 people who might have IBS-D 
who seek treatment, net potential savings to NHS is £12,721,891. ConClusions: 
Inclusion of a novel IBS diagnostic blood panel in the diagnostic pathway has 
the potential for significant cost savings due to the avoidance of unnecessary 
testing.
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objeCtives: Current guidelines recommend a positive strategy based on symp-
tom criteria without alarm features vs diagnostic exclusion which includes several 
laboratory and diagnostics procedures to exclude other organic conditions. A novel 
IBS diagnostic blood panel tests for the presence of two biomarkers associated with 
IBS-D which can complement the positive strategy. This analysis assesses the cost 
impact to the Danish healthcare system by introducing this test into the diagnostic 
pathway. Methods: A budget impact model was based on a cost-minimization 
decision model developed to compare the costs associated with two possible diag-
nostic pathways: (1) diagnostic pathway with a novel IBS diagnostic blood panel and 
(2) exclusionary diagnostic pathway and applied to the Danish population 18-65yrs 
old. Model structure was based on current literature and guidance from IBS expert 
clinicians. Direct medical expenses for laboratory tests, diagnostic procedures and 
visit costs were included in Danish Krone and weighted by utilization rates esti-
mated by a practicing gastroenterologist in Denmark. Indirect cost only included 
time off work based on a published Danish study. Results: Sigmoidoscopy, colo-
noscopy and SBFT were the most common diagnostic procedures reported with 
estimated utilization rates of 35%, 35% and 15%, respectively. Corresponding charges 
were kr4819, kr4819 and kr1861, respectively. Estimated total base case charges 
for the IBS diagnostic blood panel pathway (assumes 75% of test positive patients 
receive IBS-D treatment) vs the exclusionary pathway were kr11,237 vs kr12,284, 
respectively. If clinicians use the test 50% of the time for the 30% of the estimated 
57,490 people who might have IBS-D who seek treatment, net savings to the Danish 
healthcare system is kr30,095,980. Cost neutrality occurs if 37% of the “test positive” 
patients seek IBS treatment. ConClusions: This economic evaluation indicates 
that a positive strategy may be further enhanced with a novel IBS diagnostic blood 
panel leading to significant cost savings.
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objeCtives: The diagnosis of diarrhea predominant irritable bowel syndrome 
(IBS-D) is based on clinical presentation and several laboratory and diagnostic pro-
cedures to exclude other organic conditions. A novel IBS diagnostic blood panel has 
been developed which tests for the presence of two biomarkers associated with 
IBS-D. This study assesses the cost implications associated with introducing this 
test into the diagnostic pathway. Methods: A cost-minimization (CM) decision 
tree model was constructed to compare the costs associated with two possible 
diagnostic pathways: (1) diagnostic pathway with novel IBS diagnostic blood panel 
and (2) exclusionary diagnostic pathway (i.e. standard of care). Model structure 
was based on current literature and guidance from IBS expert clinicians. Costs for 
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objeCtives: Polymerase chain reaction (PCR) techniques could provide an ear-
lier diagnosis than traditional techniques (TT) to identify chronic infections in 
patients with musculoskeletal implants. The aim was to determine costs associ-
ated to microorganism’s diagnosis in sonicate samples of musculoskeletal implants, 
comparing the addition of a PCR technique (UnyveroTM i60-ITI) to TT versus TT 
only. Methods: A preliminary cost analysis was developed to estimate the hos-
pital costs in patients admitted at Fundación Jimenez Diaz Hospital (May-2014 to 
April-2015) for musculoskeletal implant removal due to chronic infection suspect. 
Sonicated samples were tested for microbiological diagnosis using TT. Additionally, 
samples were tested using UnyveroTM i60-ITI. Medical hospitals records were 
reviewed for data collection: sociodemographic data; type, dosing and antibiotic 
treatments; and hospital length of stay (LOS). Intravenous vancomycin and cef-
tazidime were selected as the initial empiric treatment. Replacement to a specific 
antibiotic was performed after microbiological diagnosis. Total estimated costs (€ , 
2015) included antibiotic treatment, hospital stay (€ 1,006 per day) and UnyveroTM 
i60-ITI kits (€ 350 per kit) costs. Results: Ten patients were retrieved for prelimi-
nary analysis (average age: 75.39±6.31 years; 20% men). Hip (40%) and knee (40%) 
were the most frequent implant sites. Average period from implant removal to final 
diagnosis lasted 4.60±1.35 days with TT. UnyveroTM i60-ITI diagnosis was available 
24h after removal. LOS was 24.4 days for TT and 23.3 days for UnyveroTM i60-ITI 
added to TT. The average antibiotic treatment cost was € 1,016.01 for TT and € 976.84 
for UnyveroTM i60-ITI added to TT. Hospital stay cost was € 25,591.26 for TT and 
€ 24,361.98 for UnyveroTM i60-ITI added to TT. The use of UnyveroTM i60-ITI reduced 
average total costs in € 840.67. ConClusions: UnyveroTM i60-ITI PCR for microbio-
logical identification in musculoskeletal implants sonicated is associated to faster 
diagnosis and shorter hospital stays than traditional techniques only, allowing cost 
savings at hospital level.
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objeCtives: To perform economic evaluation of donor breast milk (DBM) (using 
clinical breast pump) or artificial formula (AF) for premature infants in the neonatal 
intensive care unit (NICU) for Russian healthcare setting. Methods: We calculated 
the cost of providing 100 ml of DBM using clinical breast pump and 100 ml of AF for 
premature infants in the NICU. The total cost of providing DBM was measured as: 
the breast pump cost, the individual pumping set cost and staff costs. The cost of 
providing AF was calculated using the mean cost per 100 ml for powdered AF and 
staff costs. We also calculated the cost per averted case of necrotizing enterocolitis 
(NE) for premature infant when breastfeeding instead of the AF is used. The cost 
of the averted NE was obtained using the difference in cost of feeding during the 
period, required for NE development and number of patients “needed to treat” (NNT) 
to prevent 1 NE case derived from the clinical trials. Besides we calculated the DBM 
cost when breast milk fortifier (BMF) is added for low-weight infants. Results: The 
costs per 100 ml of AF and DBM were similar (0,67 EUR and 0,77 EUR respectively). 
The cost per averted case of NE was 344,5 EUR within 35 days that is less than NE 
treatment. The difference in costs (in favor of AF) amounted to 2,87 EUR per 100 ml 
with the use of BMF. ConClusions: The cost of DBM is comparable to the cost of 
AF, with a significant DBM clinical benefit. The costs per averted NE within 35 days 
shows that DBM is acceptable from the position of Russian health care system. 
When calculating the costs of DBM with the use of BMF, DBM costs exceed those 
for AF for more than 5 times.
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objeCtives: The material cost for reusing intermittent urinary catheters is lower 
than to use single-use catheters. These cost savings are misleading since com-
plications may increase and lower compliance to the therapy can be expected, 
necessitating use of the second choice therapy form with even more complica-
tions, i.e. an indwelling catheter. The purpose of this cost-comparison study was 
to compare single-use of coated catheters to re-use of non-coated catheters in a 
group of individuals performing intermittent catheterization where some of them 
fail their first choice therapy and switch to an indwelling catheter. Methods: A 
1-year Markov simulation model with monthly cycles was developed for users of 
daily intermittent catheterization. Individuals who used 4 catheters/day (single-use) 
were compared to individuals who re-used their catheters (1 catheter/day). After 
one month’s use, 18% of the patients in the single-use group were assumed to fail 
their treatment and switch to indwelling catheter. The corresponding frequency in 
the re-use group was 35%. The model was populated with risks from the literature 
for complications (e.g. symptomatic UTI, UTI resistant to antibiotics, pyelonephritis, 
bacteremia, epididymitis, strictures, bladder stones) as well as catheter and health-
care costs for single-use, re-use and indwelling catheters, respectively. Results: 
The total annual catheter cost per patient was 2188 euros (including 163 euros for 
indwelling catheters) in the single-use group and 817 euros (including 317 euros 
for indwelling catheters) in the re-use group. The total annual cost per patient for 
PMD38
DO NOt OverlOOk yOur cOuNtry-sPecIfIc characterIstIcs: the case Of 
barOreflex actIvatION theraPy (bat) fOr the treatMeNt Of resIstaNt 
hyPerteNsION
Soto M, Llach K, Sampietro-Colom L
Hospital Clínic Barcelona, Barcelona, Spain
objeCtives: To assess clinical effectiveness, cost-effectiveness, and budget impact 
of Baroreflex Activation Therpay (BAT) in comparison with optimal medical treat-
ment from a hospital and societal perspective in Spain. Methods: Clinical effec-
tiveness analysis was based on studies collected from medical databases and grey 
literature. Cost effectiveness and budget impact analysis was based on a Markov 
model using epidemiological data, risk functions and clinical management in 
Spain. Results: In a simulated cohort of 55-year-old non-smoker Spanish patients 
with resistant hypertension, BAT significantly reduced the number of heart attacks, 
heart failures, strokes, end-of-stage renal disease and liver transplantations. BAT 
produced 0.78 additional quality-adjusted life years with an incremental societal 
cost of 50.400€ . The resulting incremental cost-effectiveness ratio (65.000€ per 
QALY) was substantially larger than the one estimated for the Northern European 
population (7.800€ per QALY). Qualitative results were robust to all-parameter vari-
ations. ConClusions: Local health characteristics –both, epidemiological data and 
clinical management– have a large weight on cost-effectiveness results.
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objeCtives: The objective of this study was to compare the one-year costs 
related to cardiac adverse events post-index procedure discharge of Absorb and 
Xience. Methods: Using resource use data from ABSORB II, which comprised of 
501 patients randomized 2:1, one-year cardiac-related adverse event costs were 
calculated for the Absorb and Xience groups in 5 countries (France, Germany, 
Italy, The Netherlands, and Spain). Unit costs from the perspective of the health 
system were taken from publicly available data sources (2014 level). Costs were 
calculated by lipid control and diabetic status, both at baseline. Resource use 
categories included hospital admissions, outpatient visits, and cardiac diagnostic 
tests. Results: Mean country costs ranged between 1,140-1,880 Euros for Absorb 
and between 1,310-2,420 Euros for Xience. Mean country-specific per patient cost 
differences (Absorb minus Xience) were 170 Euros in France, 220 Euros in The 
Netherlands, 250 Euros in Germany, 420 Euros in Italy, and 540 Euros in Spain. 
Cost-savings were mainly attributable to the 1.5 unit reduction in mean num-
ber of subsequent percutaneous coronary interventions (PCIs) performed in the 
Absorb arm compared to the Xience group (32 versus 47 per 1,000 population for 
all country data combined). Regardless of lipid status (lipids < 2.0 mmol/l or lipids 
> 2.0 mmol/l) and diabetic status at baseline, cardiac-related adverse event costs 
were reduced with Absorb. Patients with a lipid profile > 2.0 mmol/l at baseline 
had mean country costs that ranged between 1,240-1,930 Euros for Absorb and 
between 1,380-2,540 Euros for Xience. Patients with diabetes at baseline had mean 
country costs that ranged between 1,250-1,920 Euros for Absorb and between 
1,380-3,190 Euros for Xience. ConClusions: These findings suggest potential 
short term cost-savings with Absorb compared to Xience as a result of the reduced 
mean number of repeat PCIs. Future research is necessary to study total direct and 
indirect cost and long-term costs of each intervention.
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objeCtives: ISO 15197:2003, states that 95% of the glucose results shall fall within 
±15 mg/dl for concentrations ≤ 75 mg/dl and within ±20% for > 75 mg/dl. Some 
measures which may fall into the recommended thresholds would be out of the 
limits of good metabolic control, not permitting to adjust the therapy, increas-
ing the complication risk, and raising the associated costs. The objective was 
to estimate the annual cost saving in Spain by using glucose meters with better 
accuracy. Methods: Two samples of true and read values were created accord-
ing to type 1 and 2 diabetes (T1D, T2D) Spanish population data. Proportion of 
readings into the recommended thresholds whose true values were out of the 
limits was calculated. The complication risk associated with those false readings 
was estimated from the clinical trials, and the cost to manage complications was 
calculated from public costs. Cost of strips was included to estimate the total cost. 
The annual cost saving was the difference between the total cost (2015 € ) of all 
Spanish patients in the base case (accuracy level, A20%) and other scenarios (A15%, 
A10%, and A5%). Results: 100% of T1D (n: 116,160) and 32.2% of T2D patients (n: 
957,511) will often need glycaemic self-monitoring, with a cost around 168 mill€ . 
Not detected hyper/hypoglycemia values were estimated: 119,302; 81,025, 55,915 
and 27,332 in A20%, A15%, A10%, and A5%, respectively. Total cost was 193.94 mill€ ; 
183.94 mill€ , 178.29 mill€ , and 172.98 mill€ , respectively, leading a saving cost of 
10.006 mill€ , 15.657 mill€ and 20.960 mill€ , by changing from A20% to A15%, A10% 
and A5% scenario. ConClusions: Blood glucose meters with better accuracy 
leads to decrease complications risk which is associated with cost savings: when 
meters accuracy increases from 20% to 15% and 10%, cost savings are 5.9%, 9.3%, 
and 12.4% on total strips cost.
